Cognition Therapeutics, Inc., a privately held biopharmaceutical company, is focused on the development of a pipeline of disease-modifying small molecule drug candidates that are designed to normalize the impaired membrane trafficking pathways that are the root cause of many CNS disorders. By so doing, Cognition’s drug candidates aim to protect and restore synaptic function, thereby preserving brain health. The Company's lead candidate, Elayta™, is currently in Phase 2 development for the treatment of mild-to-moderate Alzheimer's disease. Cognition’s three ongoing clinical trials – SPARC, SNAP and SHINE – are supported by grants from the National Institute on Aging.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):